About RetInSight
RetInSight GmbH was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable individuals affected by retinal disease to maintain their full vision preserving quality of life and lifelong autonomy.
To this goal, we are developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to detect and monitor the following retinal diseases: Intermediate AMD, geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most prevalent age-related diseases that lead to visual impairments in today’s world.
Our Vision
Preserve eyesight throughout lifetime
Our Mission
Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables efficient and economic patient management together with highest medical quality for diagnosis and monitoring in retinal diseases:
For anyone, any time and at any location, by supporting networked care in ophthalmology with the help of AI technology and digital data.
Our Story
Prof. Dr. Ursula Schmidt-Erfurth, MUV Medical University of Vienna (Host) and Dr. Amir Sadeghipour (Fellow) receive an FFG Spin-off Fellowship Grant that enables the spin-off
Foundation of RetInSight by Prof. Dr. Ursula Schmidt-Erfurth, Dr. Amir Sadeghipour, and Corinna zur Bonsen-Thomas
RetInSight commences clinical trial service business (cAIre)
ISO 13485 certification by TUEV SUED
CE MDR-certification and commercial launch of RetInSight Fluid Monitor
CE MDR-certification and commercial launch of RetInSight GA Monitor
Release of Fluid Monitor upgrade
ISO 27001 certification by TUEV SUED
Consortium member of the EU-funded I-SCREEN project
Acquisition of RetInSight by Topcon Healthcare, Inc.
FAQs
What does RetInSight do?
RetInSight develops AI-based software as medical device (both CE-certified and for use outside of clinical routine) for the quantitative analysis of OCT images in retinal diseases. The solutions support eye care professionals and clinical research organizations by providing objective, layer‑specific structural information derived from routine OCT imaging.
Is RetInSight part of Topcon?
Yes. RetInSight was acquired by Topcon Healthcare in 2025 and operates as part of the Topcon group while maintaining its Vienna‑based AI research and development expertise.
Where is RetInSight based?
RetInSight is headquartered in Vienna, Austria, and operates globally as part of the Topcon Healthcare network.
Which markets does RetInSight serve?
RetInSight provides solutions for both:
- Clinical routine (for eye care professionals using OCT in daily practice), and
- Clinical research (for sponsored trials in nAMD, DME, RVO, and GA).
The company serves customers in Europe for clinical routine and worldwide for clinical research.
How does RetInSight protect patient data?
All OCT data processed through RetInSight’s solutions is:
- pseudonymized
- encrypted in transit and at rest
- handled under strict access‑control and audit‑log procedures
No personally identifiable information is stored.